Although the phase III clinical trial was a failure, Neurochlore was able to retrieve data that could be promising. Indeed, we are convinced that Bumetanide works on sub-populations, defined by more specific criteria that were not considered in the selection of the initial trial. We have entered into a partnership with the company Quinten Health Information note on the re-use of your health data

IBEN will give a satellite conference at the FENS 2022, an european congress of neurosciences. The conference, which take place on July 7 and 8 at RIVE Montparnasse, will focus on the Neuroarcheology of the brain disorders and GABA signals. It will be organized by Yehezkel Ben-Ari & Nick Spitzer and will include many renowed IBEN hosts a satellite conference at FENS 2022

Short video depicting the hypothesis that autism and developmental disorders are generated in utero and how identification of the alterations they produce will enable their early prediction and novel treatments.

Being born is not easy. Mammals need to pass through the birth canal before coming out into this world, and to do so the head (and whole body) undergoes a harsh squeezing. Thankfully, the newborn prepares for this stressful event that transitions life from in-utero to ex-utero. But these events (some, or all of them) Smaller brain volumes after birth by Cesarean Section

How is it possible that drugs used to sedate or calm people, called Benzodiazepines, can induce transient awakenings in comatose patients? In our latest Commentary in Translational Medicine Communications Yehezkel Ben-Ari hypothesizes that a dysregulation of GABAergic activity underlies this seemingly contradictory effect. Extensive experimental work suggests that after brain damage and a large variety Sleeping pills that cause “awakenings”?

Since our groundbreaking positive results on the use of Bumetanide (a highly selective antagonist of the NKCC1 chloride importer) to treat autism, first in a pilot open trial and then in two double-blind clinical trials, numerous independent trials have confirmed these results. A new report by Christopher Gillberg’s group in Sweden (addressed in our recent A new report on the promising use of Bumetanide treatment for autism

Huntington’s disease, a dominant heritable disease that manifests in mid-adulthood, is caused by expansion of a polyglutamine tract within the huntingtin protein (HTT). The mutation leading to the polyglutamine tract confers a toxic gain of function phenotype resulting in neurodegeneration that is most severe in the striatum. Despite its “late” symptomatic manifestation, there are several A Huntington’s disease study supporting the Neuroarcheology concept

The activity of the neurotransmitter GABA, the main inhibitory transmitter in the brain, follows a developmental sequence. In early development GABA excites neurons via type A GABA receptors (GABAAR), and later it inhibits them. In addition, during the critical period of birth, as a protective mechanism, GABA becomes temporarily inhibitory. Five years ago, we showed The GABA developmental sequence is altered in a mouse model of Rett Syndrome

How does the brain prepare for birth? Several indirect lines of evidence in Humans suggest that the velocity at which the brain grows in utero slows down during the third trimester, a process that will make sense knowing that the head should be able to fit through the birth canal during delivery. In our recent No stop-growing signal around birth in a rodent model of autism